Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Peter Feinberg, a director of Immuneering Corp (NASDAQ:IMRX), acquired 25,000 shares of Class A Common Stock on June 18, 2025, in a purchase transaction. The price per share was $2.5275, with the trades executed at prices ranging from $2.07 to $2.96. The timing appears strategic, as IMRX has shown strong momentum with a 79% return over the past year and an 8% gain in the last week.
The total value of the purchase amounted to $63,187. Following the transaction, Feinberg directly owns 136,766 shares of Immuneering Corp. According to InvestingPro analysis, the company maintains strong liquidity with a current ratio of 7.48 and holds more cash than debt on its balance sheet, though it is currently experiencing rapid cash burn.
Feinberg also indirectly owns shares through entities where he serves as a General Partner: 392,242 shares through PF Associates L.P., 476,615 shares through PEF LLC, and 115,441 shares through S4K Investments LLC. InvestingPro analysis suggests the stock is currently undervalued, with 10+ additional insights available to subscribers.
In other recent news, Immuneering Corporation announced positive interim data from its Phase 2a clinical trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel for first-line pancreatic cancer patients. The trial reported a 94% overall survival rate and a 72% progression-free survival rate at six months, significantly outperforming standard care benchmarks. Immuneering also noted a favorable tolerability profile with no Grade 3 or higher adverse events in most categories. Mizuho (NYSE:MFG) responded to these developments by raising its price target for Immuneering to $10 from $8 and maintained an Outperform rating, citing the drug's potential as a "best-in-class" treatment. The company plans to increase trial enrollment to approximately 50 patients and aims to initiate a pivotal trial in 2026. Additionally, Immuneering held its Annual Meeting of Stockholders, where three Class I directors were elected, and the company's independent registered public accounting firm was ratified. This meeting saw participation from approximately 69.1% of the outstanding Class A common stock. Immuneering's recent developments highlight its ongoing efforts in advancing treatment options for pancreatic cancer.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.